# OnCo record gastric (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/gastric/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "gastric" ;
  schema:name "Gastric & gastro-oesophageal junction cancer"@en ;
  schema:alternateName "STAD"@en, "TCGA-STAD"@en, "stomach adenocarcinoma (TCGA STAD cohort)"@en ;
  schema:description "A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."@en ;
  schema:url <https://onco.cc/cancers/gastric/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Stomach_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q189588> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434>, <https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-gastrointestinal-cancers/>, <https://www.cancer.gov/types/stomach/hp/stomach-treatment-pdq> ;
  onco:tag "gi", "spike" ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/hipec/>, <https://onco.cc/technologies/fapi-pet/>, <https://onco.cc/technologies/gastric-endoscopic-screening/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/companion-diagnostic/>, <https://onco.cc/technologies/endoscopic-resection/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/cldn18-2/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/fap/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/her2-testing-assays/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/catumaxomab/>, <https://onco.cc/drugs/tegafur-gimeracil-oteracil/> ;
  onco:companies <https://onco.cc/companies/neonc-technologies/>, <https://onco.cc/companies/askgene-pharma/>, <https://onco.cc/companies/astellas/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/beone/>, <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/carsgen/>, <https://onco.cc/companies/remegen/>, <https://onco.cc/companies/keymed/> ;
  onco:institutions <https://onco.cc/institutions/ncc-japan/>, <https://onco.cc/institutions/snuh/>, <https://onco.cc/institutions/samsung-medical-center/>, <https://onco.cc/institutions/asan-medical-center/>, <https://onco.cc/institutions/jfcr/>, <https://onco.cc/institutions/sysucc/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/gastric-cancer-signalling/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/cps/>, <https://onco.cc/terms/siewert-classification/>, <https://onco.cc/terms/lauren-classification/>, <https://onco.cc/terms/peritoneal-metastasis/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/adcc/>, <https://onco.cc/terms/ild/>, <https://onco.cc/terms/flot-term/> ;
  onco:trials <https://onco.cc/trials/symbiotic-gi-16/>, <https://onco.cc/trials/nct07362186/>, <https://onco.cc/trials/nct07385703/>, <https://onco.cc/trials/aspen-06/>, <https://onco.cc/trials/nct06532006/>, <https://onco.cc/trials/nct07673887/>, <https://onco.cc/trials/nct06177041/>, <https://onco.cc/trials/nct06504732/>, <https://onco.cc/trials/nct07103668/>, <https://onco.cc/trials/int-0116/>, <https://onco.cc/trials/nct05427383/>, <https://onco.cc/trials/nct05980481/>, <https://onco.cc/trials/nct06731478/>, <https://onco.cc/trials/nct06901531/>, <https://onco.cc/trials/nct06764875/>, <https://onco.cc/trials/nct07518147/>, <https://onco.cc/trials/nct06221748/>, <https://onco.cc/trials/nct07221149/>, <https://onco.cc/trials/nct07217704/>, <https://onco.cc/trials/nct05144854/>, <https://onco.cc/trials/nct07431281/>, <https://onco.cc/trials/nct07023315/>, <https://onco.cc/trials/nct07315750/>, <https://onco.cc/trials/spotlight-glow/>, <https://onco.cc/trials/nct07522151/>, <https://onco.cc/trials/nct06123494/>, <https://onco.cc/trials/nct06296706/>, <https://onco.cc/trials/nct04342910/> ;
  onco:people <https://onco.cc/people/mitsuru-sasako/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-spotlight-lancet-2023/> ;
  onco:journals <https://onco.cc/journals/gastric-cancer/>, <https://onco.cc/journals/journal-of-gastric-cancer/>, <https://onco.cc/journals/journal-of-gastrointestinal-cancer/> ;
  onco:pipeline <https://onco.cc/drugs/cmg901/>, <https://onco.cc/drugs/satricabtagene-autoleucel/>, <https://onco.cc/drugs/disitamab-vedotin/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/technologies/fapi-pet/>, <https://onco.cc/drugs/pf-08634404/>, <https://onco.cc/drugs/shr-8068/>, <https://onco.cc/drugs/lm-108/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/mrg002/>, <https://onco.cc/drugs/lm-302/>, <https://onco.cc/drugs/evorpacept/>, <https://onco.cc/drugs/hlx22/>, <https://onco.cc/drugs/asp2138/>, <https://onco.cc/drugs/m108/>, <https://onco.cc/drugs/iah0968/>, <https://onco.cc/drugs/mcla-129/>, <https://onco.cc/drugs/trk-950/>, <https://onco.cc/drugs/xnw27011/>, <https://onco.cc/drugs/cinrebafusp-alfa/>, <https://onco.cc/drugs/azd4360/>, <https://onco.cc/drugs/absk061/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/bdc-4182/>, <https://onco.cc/drugs/azd7789/>, <https://onco.cc/drugs/spevatamig/>, <https://onco.cc/drugs/azd5863/>, <https://onco.cc/trials/herizon-gea-01/>, <https://onco.cc/trials/clarity-gastric01/>, <https://onco.cc/drugs/bemarituzumab/>, <https://onco.cc/trials/fortitude-101/>, <https://onco.cc/ideas/idea-biomarker-quadruplet-gastric/>, <https://onco.cc/ideas/idea-peritoneal-directed-gastric/>, <https://onco.cc/pairings/her2-gastric-sequence/>, <https://onco.cc/pairings/cldn18-antibody-then-adc/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:standardOfCare <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/satricabtagene-autoleucel/>, <https://onco.cc/drugs/cmg901/>, <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/endoscopic-resection/>, <https://onco.cc/trials/matterhorn/>, <https://onco.cc/drugs/flot/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/trials/classic/>, <https://onco.cc/trials/toga/>, <https://onco.cc/trials/herizon-gea-01/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/pairings/her2-gastric-sequence/>, <https://onco.cc/trials/checkmate-649/>, <https://onco.cc/trials/keynote-859/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/trials/spotlight-glow/>, <https://onco.cc/drugs/zolbetuximab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/ideas/idea-biomarker-quadruplet-gastric/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/terms/msi/>, <https://onco.cc/trials/destiny-gastric04/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/rainbow/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/trials/clarity-gastric01/>, <https://onco.cc/drugs/cmg901/>, <https://onco.cc/drugs/satricabtagene-autoleucel/>, <https://onco.cc/pairings/cldn18-antibody-then-adc/>, <https://onco.cc/drugs/trifluridine-tipiracil/>, <https://onco.cc/terms/peritoneal-metastasis/>, <https://onco.cc/technologies/hipec/>, <https://onco.cc/ideas/idea-peritoneal-directed-gastric/> .